Neuropace/$NPCE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Neuropace
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.
Ticker
$NPCE
Sector
Primary listing
Employees
209
Headquarters
Website
Neuropace Metrics
BasicAdvanced
$352M
-
-$0.84
1.92
-
Price and volume
Market cap
$352M
Beta
1.92
52-week high
$18.98
52-week low
$5.45
Average daily volume
154K
Financial strength
Current ratio
5.468
Quick ratio
4.416
Long term debt to equity
357.717
Total debt to equity
367.934
Interest coverage (TTM)
-2.31%
Profitability
EBITDA (TTM)
-19.659
Gross margin (TTM)
75.74%
Net profit margin (TTM)
-29.29%
Operating margin (TTM)
-22.43%
Revenue per employee (TTM)
$420,000
Management effectiveness
Return on assets (TTM)
-12.39%
Return on equity (TTM)
-176.94%
Valuation
Price to revenue (TTM)
3.716
Price to book
18.09
Price to tangible book (TTM)
18.09
Price to free cash flow (TTM)
-20.026
Free cash flow yield (TTM)
-4.99%
Free cash flow per share (TTM)
-0.531
Growth
Revenue change (TTM)
23.32%
Earnings per share change (TTM)
-22.87%
3-year revenue growth (CAGR)
27.32%
3-year earnings per share growth (CAGR)
-21.95%
What the Analysts think about Neuropace
Analyst ratings (Buy, Hold, Sell) for Neuropace stock.
Bulls say / Bears say
NeuroPace achieved steady double-digit revenue growth in 2025, with Q1 revenue rising 24% year over year to $22.5 million and Q2 revenue up 22% year over year to $23.5 million, driven by greater adoption of its key RNS System (TradingView/Reuters • GlobeNewswire).
Gross margin improved to 77.0% in Q1 2025 (up from 73.6% in Q1 2024) and to 77.1% in Q2 2025 (up from 73.4% in Q2 2024), exceeding guidance and reflecting better manufacturing efficiency (TradingView/Reuters • GlobeNewswire).
NeuroPace bolstered its financial flexibility by securing a new $75 million credit facility with MidCap Financial. This replaces prior debt, offers better terms, and extends maturity by five years, supporting expansion of the RNS System and growth plans (GlobeNewswire).
NeuroPace continues to post net losses in 2025, signaling an uncertain path to profitability. Net loss for Q1 2025 was $6.6 million, and Q2 2025 net loss was $8.7 million, despite revenue growth (TradingView/Reuters • GlobeNewswire).
Unfavorable results in the NAUTILUS clinical trial have raised concerns among investors; the one-year data did not meet the main effectiveness goal, triggering a 33.7% drop in the stock price on May 27, 2025 (RTTNews).
NeuroPace reported negative free cash flow and shrinking cash reserves, highlighting ongoing cash burn. Cash outflow was $2.3 million in Q2 2025, with cash balances dropping to $62.1 million as of June 30, 2025—demonstrating a reliance on external funding (GlobeNewswire • GlobeNewswire).
Data summarised monthly by Lightyear AI. Last updated on 11 Oct 2025.
Neuropace Financial Performance
Revenues and expenses
Neuropace Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Neuropace stock?
Neuropace (NPCE) has a market cap of $352M as of October 18, 2025.
What is the P/E ratio for Neuropace stock?
The price to earnings (P/E) ratio for Neuropace (NPCE) stock is 0 as of October 18, 2025.
Does Neuropace stock pay dividends?
No, Neuropace (NPCE) stock does not pay dividends to its shareholders as of October 18, 2025.
When is the next Neuropace dividend payment date?
Neuropace (NPCE) stock does not pay dividends to its shareholders.
What is the beta indicator for Neuropace?
Neuropace (NPCE) has a beta rating of 1.92. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.